Economic Recession Affects Rates of Cancer Incidence and Treatment

Unemployed patients forgo testing and life-saving therapies
August 2011 Vol 4, No 4, Special Issue
Wayne Kuznar

Ronald D. Ennis, MD

The number of cancer diagnoses and the number of patients adhering to cancer treatments decline with high unemployment rates during an economic recession, based on a new an alysis presented by Ronald D. Ennis, MD, Director of Radiation Oncology, St Luke’s-Roosevelt Hospital, New York City.

Dr Ennis and colleagues assessed the effect of economic cycles on the diagnosis and treatment of cancer, hypothesizing that during an economic recession, people would choose to forgo screenings and treatments for cancer.

The investigators anticipated that this effect would be more pronounced for a cancer for which a screening test is available and that has minimal presenting symptoms (eg, breast cancer). In contrast, there would be less of an effect for a cancer that has no screening test and has symptoms that are harder to ignore (eg, pancreatic cancer). Breast and pancreatic cancers were chosen as these 2 types of cancers meeting the study criteria.

Unemployment was used as a measure of recession per monthly data obtained from the Bureau of Labor Statistics. Surveillance, Epidemi ology and End Results (SEER) data were used for monthly incidence rates for treatment with radiotherapy and surgery for all cancers, and for breast and pancreatic cancers separately. Data were used from the original 9 SEER registries for the period between 1973 and 2007.

Because a dramatic increase took place in the use of radiotherapy for breast cancer between 1990 and 2000—as a result of the emergent use of lumpectomy plus radiotherapy as an alternative to mastectomy—data for that decade were excluded from the analysis of the effect of the economy on the use of radiotherapy in breast cancer.

“As expected, the effect was much more profound for breast cancer than for pancreatic cancer,” said Dr Ennis. Overall, for all cancers, every 1% increase in unemployment was accompanied by a 2.7% decrease in cancer incidence (or diagnosis), an 8.7% decrease in the use of radiotherapy, and a 12.1% decline in the use of surgery.

The correlation was higher in breast cancer: every 1% increase in unemployment resulted in a 7.4% decrease in breast cancer diagnosis, a 16.8% decline in the use of radiotherapy for breast cancer treatment, and a 23.9% reduction in breast cancer surgeries.

“There was a smaller but still present effect on the use of treatment during unemployment for pancreatic cancer, but much less than for all cancers and dramatically less than for breast cancer,” Dr Ennis said. No significant relationship was found between unemployment and the diagnosis of pancreatic cancer, a 1.5% decrease in the use of radiotherapy for pancreatic cancer with every 1% increase in unemployment, and an 8.5% decrease in surgery for this cancer.

The impact of a recession on administration of cancer treatments may go beyond unemployment to include the fear of losing one’s job, said Dr Ennis. “There might be a cohort of patients who, despite not having lost their job or fear losing their job…would still go for their mammogram or biopsy, but then, when faced with the daunting task of going through treatment and potentially having to be out of work or copays…don’t carry through with the treatment because of those barriers,” he said.

Related Items
The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Pediatric Cancer
Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Emerging Therapies
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Emerging Therapies
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Cholangiocarcinoma
Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Biomarkers
Last modified: September 6, 2011
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME